IP Library Granted Patent US 7,201,912
Granted Patent B2
US 7,201,912 · App. 10/402,466 · Granted Apr 10, 2007

Recombinant immunogenic compositions and methods for protecting against lethal infections from

Assignee: Emergent BioDefense Operation Lansing Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,201,912
App. No.
10/402,466
Granted
Apr 10, 2007
Kind
B2
Abstract

Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis having a variant of recombinant Bacillus anthracis protective antigen (rPA) and a variant of recombinant Bacillus anthracis lethal factor (rLF). These proteins may be expressed separately or as a fusion protein. The recombinant proteins are produced in an avirulent strain of Bacillus anthracis that overproduces the desired antigens. The compositions and methods induce the animal host to produce antibodies against a virulent strain of Bacillus anthracis.

Claims (8)

1. An immunogenic composition comprising a recombinant B. anthracis PA (rPA) protein comprising the amino acid sequence set forth in SEQ ID NO: 9 and a recombinant B. anthracis LF (rLF) protein comprising the amino acid sequence set forth in SEQ ID NO: 6.

2. The composition of claim 1 , further comprising at least one adjuvant.

3. The immunogenic composition of claim 2 , wherein said adjuvant is aluminum hydroxide, an immunostimulatory sequence (ISS), CpG, or calcium phosphate.

4. A method of producing an immunogenic response in an animal comprising the step of: administering to an animal the immunogenic composition of claim 1 .

5. The method of claim 4 , wherein the composition comprises rPA to rLF at a ratio of 5:2.

6. The method of claim 4 , further comprising the step of administering at least one adjuvant to the animal.

7. The method of claim 5 , wherein said adjuvant is aluminum hydroxide, an immunostimulatory sequence (ISS), CpG, or calcium phosphate.

8. The method of claim 7 , wherein the composition comprises 50 μg rPA and 20 μg rLF per 0.5 ml of the aluminum hydroxide.

Assignments (4)
WELLS FARGO BANK, NATIONAL ASSOCIATION Recorded Sep 3, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
Reel/Frame 068828/0488 →
SECURITY INTEREST Recorded May 18, 2023
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 063689/0954 →
CHANGE OF NAME Recorded Feb 12, 2007
From: BIOPORT CORPORATION
To: EMERGENT BIODEFENSE OPERATIONS LANSING INC.
Reel/Frame 018915/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2003
From: PARK, SUKJOON; GIRI, LALLAN
To: BIOPORT CORPORATION
Reel/Frame 013745/0330 →
Continuity (2)
Provisional Application 6037215200 · Apr 12, 2002
Related Publication 20040028695A1 · Feb 12, 2004